AI in Pathology Market: Growth, Size, Share, and Trends

Report Code HIT 8721
Published in Nov, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

AI in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical workflow), End User (Hospital, Labs, Pharma/Biotech), & Region - Global Forecast to 2029

Overview

The global AI in pathology market is projected to reach USD 169.8 million by 2029 from USD 82.8 million in 2024, at a CAGR of 15.4 % over the forecast period. Al algorithms can now be applied to scanning digital pathology images to identify and characterize different anomalies such as tumors, cancerous cells, and structures in tissue that could help pathologists identify and quantify the critical features that could aid in better diagnosis and the decision to start treatment. AI in pathology provides several advantages, such as accurate results, efficiency, and better patient care. This system can help pathologists to detect and characterize abnormalities, make diagnoses, and predict the outcomes of the disease through large datasets and algorithms that are trained by annotated pathology images.

Integration of AI in multiplex imaging, adoption of cloud-based AI platforms in pathology, increasing use of automated AI-assisted QC systems, and rising FDA approvals for AI/ML systems are some of the major factors accelerating market growth. Some of the other growth drivers for the market include a growing demand for higher technology solutions, rising levels of misdiagnoses, increased funding programs to improve the standard of care towards patients, and a growing emphasis on cost containment along with hospital operation efficiency.

Attractive Opportunities in the AI in Pathology Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to government healthcare initiatives and AI policy support, R&D investments by key players and startups, and expanding healthcare infrastructure and hospital digitization.

Surge in collaborations between AI startups and healthcare institutions, and widespread deployment of AI-integrated digital pathology in cancer centers are key factors driving the market growth.

The expansion of AI-enabled diagnostic services in rural and underserved areas and the integration of AI in national cancer screening programs are factors expected to provide lucrative opportunities for market players.

The Asia Pacific AI in pathology market is expected to witness significant growth over the forecast period. due to increasing demand for precision medicine.

Limited digital infrastructure in developing countries and a shortage of skilled personnel are expected to pose a challenge to the growth of this market.

Global AI in Pathology Market Dynamics

DRIVER: Increasing cases of misdiagnosis lead to a growing need for AI in pathology

Misdiagnosis can occur when a disease or condition is either missed, misclassified, or delayed in its diagnosis. This has been such a big problem in healthcare since it leads to the provision of suboptimal and late treatment and also harm to patients, as well as increased healthcare costs. Prostate cancer, breast cancer, and thyroid cancer have proven to be among the most common cancers that are being misdiagnosed. According to a journal published in 2023 by BMJ-Quality & Safety, it is estimated that an estimated total of 800,000 Americans have wrong diagnoses yearly causing the death of 371,000 patients and permanent disabilities to 424,000.

The most common reasons for the misdiagnoses included the interpretation of scans by general pathologists instead of subspecialists, non-ordering of the necessary follow-up test by physicians, and errors made by doctors in interpreting the test results. Artificial intelligence, although still in its infancy in clinical practice, could help with the rising workloads of pathologists while simultaneously providing consistent and timely diagnostic care.

RESTRAINT: High cost of digital pathology systems

One of the reasons for low adoption of Al is a high upfront investment in establishing digital pathology systems: Al often depends on such systems for data acquisition and analysis. A typical digital pathology system will include a slide scanner, an image server, and the relevant software. These can often cost between USD 500,000 and USD 1,500,000. A full-featured scanner itself costs around USD 250,000. The average price of a digital pathology scanner in the Asia Pacific is around USD 110,000 to USD 130,000. Although large hospitals with good capital budgets can afford these systems, not very many pathologists or institutes have limited budgets or even IT support. Healthcare providers are financially constrained much more to invest in expensive technologies like digital pathology, which is most prominently found in emerging countries like India, Brazil, and Mexico. Furthermore, skilled manpower is required for the smooth management and servicing of these digital pathology systems. The prices of the digital pathology systems are supplemented by the lack of scarcity of skilled manpower to operate the digital pathology systems which is most likely to limit the adoption of the systems. Without the adoption of these systems, Al will not be able to get incorporated into pathology.

There are only a few labs in the world that are totally digital now. Some nations, such as the Netherlands or Scandinavian countries, are ahead of the curve in this area. However, in Germany or the US, the transition to digital pathology in the clinical setting is moving at a glacial pace, and so is the adoption of AI in pathology.

 

OPPORTUNITY: Growing demand for personalized medicine

Personalized medicine offers tailored treatments and prevention procedures to each individual's condition for maximum results. The adoption of this kind of medicine is on the rise due to an increase in the population aged at 65 years and above besides an increase incidence of diseases like cancer. For all these disease conditions, personalized medicine offers the opportunity for targeted therapies aimed to destroy tumor cells with minimal impact on healthy cells. According to this report, out of the 48 novel therapeutic molecular entities approved by the US FDA in 2021, 17, alongside two new cell-based therapies, were personalized medicine. Around 47% of these newly accepted personalized therapies were indicated for the treatment of cancers. A few of the important developments concerning the application of AI in pathology for personalized medicine are listed below:

  • In September 2024, Paige Al, Inc. launched Paige Alba, an Al tool developed as a clinical-grade multimodal co-pilot to advance personalized medicine and precision oncology. It provides real-time Al-driven insights for patients.
  • In March 2022, Ibex Medical Analytics Ltd. partnered with Dedalus Group. Through this partnership, the company can bring the power of artificial intelligence to digital pathology.

In personalized medicine, pathological data is required to prescribe the right therapy at the right time. AI in pathology systems offers companion algorithms for specimen slide diagnosis, which helps detect cancer cells and enable early diagnosis. Thus, the high demand for personalized medicine offers significant growth opportunities for AI in the pathology market.

CHALLENGES: Data privacy concerns

The adoption of AI in industry is limited by data privacy. In most countries, patient health information is covered under federal laws and compromises in its safety may attract litigation and financial responses. As Al used for patient care requires access to multiple health datasets, Al-based tools need to adhere to all the data security protocols implemented by governments and regulatory authorities. This is a difficult task as most Al platforms are consolidated and require extensive computing power, owing to which patient data, or parts of it, can be required to reside in a vendor's data center. The need to alleviate concerns regarding data privacy by ensuring sufficient security remains a major challenge in the market. The figure below shows the percentage of healthcare breaches reported to the US Department of Health and Human Services involving 500 or more individuals.

Global AI in Pathology Market Ecosystem Analysis

The AI in pathology ecosystem is a network involving complex distributions with various stakeholders in the process who have all contributed to the product so far. The key players for this ecosystem are AI software providers and cloud service providers, which provide scalable data platforms for hosting and processing them to cut across large data outputs from high-resolution images with diagnostics. The medical device manufacturers offer the hardware like high-resolution scanners and the imaging systems; middleware providers ensure integration with existing healthcare systems for AI solutions. Also, regulatory bodies decide on the guidelines and pathways of approvals so that the developed AI applications are safe and can comply with their standards. Data analytics solution providers convert pathology data into actionable insights to enable better decisions. This represents an interconnected ecosystem where collaboration would occur among all the technology, healthcare, and regulatory sectors to drive innovation and promote AI adoptions in pathology.

 

By offering, end-to-end solutions (integrated platforms) segment accounted for the largest segment in the AI in pathology market in 2023.

The global AI in pathology market is divided into end-to-end solutions (integrated platforms), niche point solutions, and technology. In 2023, the end-to-end solutions (integrated platforms), segment held the largest share in the global AI in pathology market. This fairly large share can be associated with the relative acceptance and use of Al-based software among pathologists.

It has many advantages, such as great adaptability and interoperability, with the automation of various pathology tasks like image analysis, data extraction, and report generation. Factors that define the adoption and advancement of Al software in pathology pose significant potential for an advance in the detection, diagnosis, and treatment of diseases.

Convolutional Neural Network is estimated to be the fastest-growing segment in the AI in pathology market

The AI in pathology market is segmented into types of neural networks, namely, Generative Adversarial Network (GAN), Convolutional Neural Network (CNN), Recurrent Neural Network (RNN), and others. The convolutional neural network segment is projected to be the fastest-growing segment over the forecast period. This segment has shown phenomenal growth, mainly due to its excellent capability to analyze complex visual data, including pathology images, extract relevant features, and provide correct diagnoses. Apart from that, CNN can locate or section out areas of interest within images and also continuously learn and enhance its performance based on new data and feedback from pathologists.

North America to witness the highest growth rate during the forecast period.

The region leading the pathology AI market, North America, is driven by existing infrastructural developments within the healthcare system, favorable regulations as well as the readiness of the market to accept such technologies as advanced diagnostics. The US and Canada are at the forefront of investing in diagnostics particularly digital pathology and artificial intelligence (AI) technologies aimed at improving diagnosis accuracy and efficiency, especially towards challenging diseases like cancer. While these and other initiatives such as the US FDA's fast-tracked approval of advanced medical equipment like ‘AI by the NCI, have spurred the pathology market to embrace AI technologies quicker than any other market. Moreover, there is also interaction between technology companies and healthcare providers aimed at coming up with these solutions in North America which is also aided by government and private funding

HIGHEST CAGR MARKET IN 2023
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION

Recent Developments of AI in Pathology Market

  • In August 2023, Indica Labs Inc. launched Lung Macrodissect AI tool that transforms slide macrodissection and molecular pathology workflows.
  • In February 2024, Roche Tissue Diagnostics (RTD) collaborated with PathAI to create AI-powered digital pathology algorithms for RTD's companion diagnostics division. These image analysis algorithms are planned to be implemented on Roche’s Navify Digital Pathology platform, ensuring smooth integration into pathology labs across the globe.
  • In February 2024, the US Food and Drug Administration (FDA) approved Hologic Inc.’s Genius Digital Diagnostics System with its AI algorithm features. This system is the first FDA-approved digital cytology solution that integrates deep-learning AI with advanced volumetric imaging technology to assist in detecting pre-cancerous lesions and cervical cancer cells.
  • In January 2022, Aiforia Technologies Plc collaborated with the Mayo Clinic to establish AI-powered pathology research support architecture at Mayo Clinic to enable faster results and scalable studies in translational research.

Key Market Players

KEY PLAYERS IN THE AI IN PATHOLOGY MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in AI in Pathology Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Million/Billion (USD)
Segments covered Offering, Neural Networks, Functions, Use Case, End User
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East and Africa

 

Key Questions Addressed by the Report

Which are the top industry players in the global AI in pathology market?
Koninklijke Philips N.V. (Netherlands), F. www Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAl (Taiwan), Aiosyn (Netherlands), Paige Al, Inc. (US), Proscia Inc. (US), PathAl, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).
Which offerings have been included in the AI in pathology market report?
This report contains the following AI in pathology offering:
  • End-to-end Solutions
  • Niche Point Solutions
  • Technology
  • Hardware
    • Scanners
    • Microscopes
    • Storage Systems
Which geographical region is dominating in the global AI in pathology market?
The global AI in pathology market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share, and it also projected to register the highest growth during the forecast period.
Which end-user segments have been included in the AI in pathology market report?
The report contains the following end-user segments:
  • Pharmaceutical & Biopharmaceutical Companies
  • Hospitals & Reference Laboratories
  • Academic & Research Institutes
What is the total CAGR expected to be recorded for the AI in pathology market during 2024-2029?
The CAGR is expected to record a CAGR of 15.4 % from 2024-2029

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the AI in Pathology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
26
RESEARCH METHODOLOGY
31
EXECUTIVE SUMMARY
44
PREMIUM INSIGHTS
48
MARKET OVERVIEW
52
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Development of CNNs and advanced AI models
    - Integration of AI into multiplex imaging
    - Increasing cases of misdiagnoses in patients
    - Benefits of AI-augmented telepathology
    - Advancements in deep learning & image processing
    RESTRAINTS
    - High cost of digital pathology systems
    - Limited AI expertise and varied regulatory guidelines for medical software
    - Inadequate interoperability issues with legacy systems
    OPPORTUNITIES
    - Increasing demand for personalized medicine
    - Integration of multi-omics data
    - Predictive analytics for disease progression
    CHALLENGES
    - Insufficient data for AI algorithms
    - Data privacy & ethical concerns
    - Challenges associated with interpretability of AI models
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 INDUSTRY TRENDS
    EVOLUTION OF AI IN PATHOLOGY
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Machine learning and artificial intelligence
    - Computer vision
    COMPLEMENTARY TECHNOLOGIES
    - Cloud computing
    ADJACENT TECHNOLOGIES
    - Telepathology
  • 5.8 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia Pacific
  • 5.9 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS, BY OFFERING
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.10 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.11 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
    JURISDICTION & TOP APPLICANT ANALYSIS
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.13 END-USER ANALYSIS
    UNMET NEEDS OF END USERS
    END-USER EXPECTATIONS
  • 5.14 KEY CONFERENCES AND EVENTS, 2024–2025
  • 5.15 CASE STUDY ANALYSIS
    CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY
    CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 AI IN PATHOLOGY MARKET: BUSINESS MODELS
  • 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
    KEY USE CASES
    CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    - Case Study: Accelerated biomarker discovery and clinical trial optimization
    IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    - Drug discovery & development market
    - Medical imaging & diagnostics market
    USERS READINESS AND IMPACT ASSESSMENT
    - User readiness
    - Impact assessment
  • 5.19 TRADE ANALYSIS
    IMPORT DATA
    EXPORT DATA
AI IN PATHOLOGY MARKET, BY OFFERING
88
  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS
    INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
  • 6.3 NICHE POINT SOLUTIONS
    GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
  • 6.4 TECHNOLOGY
    RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL UPTAKE
  • 6.5 HARDWARE
  • 6.6 MICROSCOPES
    AUTOMATED ANALYSIS OF TISSUE SAMPLES FOR EFFECTIVE CONCLUSIONS TO FUEL UPTAKE
  • 6.7 SCANNERS
    IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
  • 6.8 STORAGE SYSTEMS
    ABILITY TO PROVIDE STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH
AI IN PATHOLOGY MARKET, BY NEURAL NETWORK
100
  • 7.1 INTRODUCTION
  • 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
    ABILITY TO PROVIDE HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
  • 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
    DESIGNED FOR GENERATION OF ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
  • 7.4 RECURRENT NEURAL NETWORKS (RNNS)
    ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL UPTAKE
  • 7.5 OTHER NEURAL NETWORKS
AI IN PATHOLOGY MARKET, BY FUNCTION
107
  • 8.1 INTRODUCTION
  • 8.2 IMAGE ANALYSIS
    DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
  • 8.3 DIAGNOSTICS
    RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
  • 8.4 WORKFLOW MANAGEMENT
    OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
  • 8.5 DATA MANAGEMENT
    ADVANCEMENTS IN DATA INTEGRATION & PROCESSING TO BOOST DEMAND
  • 8.6 PREDICTIVE ANALYTICS
    GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
  • 8.7 CDSS
    PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
  • 8.8 AUTOMATED REPORT GENERATION
    INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
  • 8.9 QUALITY ASSURANCE TOOLS
    RISING REGULATORY DEMANDS TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS
AI IN PATHOLOGY MARKET, BY USE CASE
117
  • 9.1 INTRODUCTION
  • 9.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & SELECTION
    - Analysis of molecular & histological data for biomarker discovery to fuel market
    TARGET VALIDATION
    - Increasing demand for precision medicine to drive market
    HIT IDENTIFICATION & PRIORITIZATION
    - Growing requirement for rapid analysis and cost efficiency to fuel uptake
    HIT-TO-LEAD IDENTIFICATION
    - Advancements in ML to support market growth
    LEAD OPTIMIZATION
    - Growing focus on therapeutic efficacy to propel market
    CANDIDATE SELECTION & VALIDATION
    - Critical requirement for regulatory approvals to drive market
  • 9.3 DISEASE DIAGNOSIS & PROGNOSIS
    INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
  • 9.4 CLINICAL WORKFLOW
    STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
  • 9.5 TRAINING & EDUCATION
    UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH
AI IN PATHOLOGY MARKET, BY END USER
131
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
  • 10.3 HOSPITALS & REFERENCE LABORATORIES
    INCREASING UPTAKE OF INFECTIOUS DISEASE DIAGNOSIS TO DRIVE MARKET
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    INCREASING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH
AI IN PATHOLOGY MARKET, BY REGION
136
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - High healthcare expenditure and improvements in cloud computing platforms to propel market
    CANADA
    - Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    UK
    - Increasing focus on drug discovery & development to boost demand
    GERMANY
    - Availability of funding for AI initiatives to fuel uptake
    FRANCE
    - Increasing adoption of big data in healthcare computing to fuel uptake
    ITALY
    - Digital transformation and innovation in healthcare to support market growth
    SPAIN
    - Workforce shortages to fuel market
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing incidence of infectious & chronic diseases to fuel uptake
    JAPAN
    - Advanced healthcare infrastructure to propel market
    INDIA
    - Growing focus on healthcare digitization to boost demand
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Strategic investments for AI adoption to support market growth
    MEXICO
    - Growth in pharmaceutical R&D to drive market
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Increasing investments in expansion of technological expertise to support market growth
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
204
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
  • 12.3 REVENUE ANALYSIS, 2019−2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Offering footprint
    - Use-case footprint
    - End-user footprint
    - Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS /SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    COMPANY VALUATION
    FINANCIAL METRICS
    BRAND/SOFTWARE COMPARISON ANALYSIS
  • 12.8 COMPETITIVE SCENARIO
    PRODUCT/SERVICE LAUNCHES & APPROVALS
    DEALS
    OTHER DEVELOPMENTS
COMPANY PROFILES
225
  • 13.1 KEY PLAYERS
    KONINKLIJKE PHILIPS N.V.
    - Business overview
    - Products/Services offered
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    HOLOGIC, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    AKOYA BIOSCIENCES, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    AIFORIA TECHNOLOGIES PLC
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    INDICA LABS INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    OPTRASCAN
    - Business overview
    - Products/Services offered
    - Recent developments
    IBEX MEDICAL ANALYTICS LTD.
    - Business overview
    - Products/Services offered
    - Recent developments
    MINDPEAK GMBH
    - Business overview
    - Products/Services offered
    - Recent developments
    TRIBUN HEALTH
    - Business overview
    - Products/Services offered
    - Recent developments
    TECHCYTE, INC.
    - Business overview
    - Products/services offered
    - Recent developments
    DEEP BIO INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    LUMEA INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    VISIOPHARM
    - Business overview
    - Products/Services offered
    AETHERAI
    - Business overview
    - Products/Services offered
    - Recent developments
    AIOSYN
    - Business overview
    - Product/Services offered
    - Recent developments
    - Recent developments
    PAIGE AI, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    PROSCIA, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    PATHAI, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    TEMPUS LABS, INC.
    - Business overview
    - Products/Services offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    KONFOONG BIOINFORMATION TECH CO., LTD.
    DOMORE DIAGNOSTICS AS
    VERILY LIFE SCIENCES, LLC
    DEEPPATH
    4D PATH INC.
APPENDIX
281
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 STUDY ASSUMPTION ANALYSIS
  • TABLE 3 RISK ASSESSMENT ANALYSIS
  • TABLE 4 AI IN PATHOLOGY MARKET: ROLE IN ECOSYSTEM
  • TABLE 5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 12 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • TABLE 13 AI IN PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS (%)
  • TABLE 15 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS
  • TABLE 16 UNMET NEEDS FOR AI IN PATHOLOGY MARKET
  • TABLE 17 END-USER EXPECTATIONS FOR AI IN PATHOLOGY MARKET
  • TABLE 18 AI IN PATHOLOGY MARKET: LIST OF CONFERENCES AND EVENTS
  • TABLE 19 IMPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020–2022 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020–2022 (USD THOUSAND)
  • TABLE 21 AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 22 AI IN PATHOLOGY MARKET FOR OFFERING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 23 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 AI IN PATHOLOGY MARKET FOR NICHE-POINT SOLUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 27 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 AI IN PATHOLOGY MARKET, BY NEURAL NETWORKS, 2022–2029 (USD MILLION)
  • TABLE 32 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 37 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 46 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY
  • TABLE 47 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 48 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 59 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 AI IN PATHOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 63 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 69 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 70 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 71 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 72 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 73 US: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 74 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 75 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 79 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 85 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 86 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 87 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 88 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 89 UK: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 90 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 91 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 95 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 96 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 100 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 101 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 105 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 106 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 110 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 111 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 121 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 122 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 126 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 127 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 128 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 132 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 133 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 137 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 138 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 142 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 148 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 149 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 153 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 154 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 158 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 159 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 163 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 164 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 169 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 170 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 174 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 175 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
  • TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022–2029 (USD MILLION)
  • TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022–2029 (USD MILLION)
  • TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 179 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
  • TABLE 180 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 181 OFFERING FOOTPRINT ANALYSIS
  • TABLE 182 USE-CASE FOOTPRINT ANALYSIS
  • TABLE 183 END-USER FOOTPRINT ANALYSIS
  • TABLE 184 REGION FOOTPRINT ANALYSIS
  • TABLE 185 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 186 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 187 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–OCTOBER 2024
  • TABLE 188 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 189 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, 2021–2024
  • TABLE 190 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 191 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED
  • TABLE 192 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 193 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 194 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−OCTOBER 2024
  • TABLE 195 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 198 HOLOGIC, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021−OCTOBER 2024
  • TABLE 199 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 200 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED
  • TABLE 201 AKOYA BIOSCIENCES INC.: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 202 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW
  • TABLE 203 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED
  • TABLE 204 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 205 INDICA LABS INC.: COMPANY OVERVIEW
  • TABLE 206 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 207 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−OCTOBER 2024
  • TABLE 208 INDICA LABS INC.: DEALS, JANUARY 2021−OCTOBER 2024
  • TABLE 209 INDICA LABS INC.: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 210 OPTRASCAN: COMPANY OVERVIEW
  • TABLE 211 OPTRASCAN: PRODUCTS/SERVICES OFFERED
  • TABLE 212 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 213 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW
  • TABLE 214 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 215 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES/APPROVALS, JANUARY 2021–OCTOBER 2024
  • TABLE 216 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 217 MINDPEAK GMBH: COMPANY OVERVIEW
  • TABLE 218 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED
  • TABLE 219 MINDPEAK GMBH: PRODUCT/SERVICE APPROVALS, JANUARY 2021–OCTOBER 2024
  • TABLE 220 MINDPEAK GMBH: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 221 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 222 TRIBUN HEALTH: COMPANY OVERVIEW
  • TABLE 223 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED
  • TABLE 224 TRIBUN HEALTH: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 225 TECHCYTE, INC.: COMPANY OVERVIEW
  • TABLE 226 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 227 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 228 TECHCYTE, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 229 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 230 DEEP BIO INC.: COMPANY OVERVIEW
  • TABLE 231 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 232 DEEP BIO INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 233 LUMEA INC.: COMPANY OVERVIEW
  • TABLE 234 LUMEA INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 235 LUMEA INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 236 VISIOPHARM: COMPANY OVERVIEW
  • TABLE 237 VISIOPHARM: PRODUCTS/SERVICES OFFERED
  • TABLE 238 VISIOPHARM: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 239 VISIOPHARM: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 240 AETHERAI: COMPANY OVERVIEW
  • TABLE 241 AETHERAI: PRODUCTS/SERVICES OFFERED
  • TABLE 242 AETHERAI: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 243 AIOSYN: COMPANY OVERVIEW
  • TABLE 244 AIOSYN: PRODUCTS/SERVICES OFFERED
  • TABLE 245 AIOSYN: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 246 AIOSYN: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 247 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 248 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 249 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 250 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–OCTOBER 2024
  • TABLE 251 PAIGE AI, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 252 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 253 PROSCIA, INC.: COMPANY OVERVIEW
  • TABLE 254 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 255 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & ENHANCEMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 256 PROSCIA, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 257 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 258 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 259 PATHAI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 260 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–OCTOBER 2024
  • TABLE 261 PATHAI, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 262 TEMPUS LABS, INC.: COMPANY OVERVIEW
  • TABLE 263 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 264 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 265 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 266 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW
  • TABLE 267 VERILY LIFE SCIENCES, LLC: COMPANY OVERVIEW
  • TABLE 268 DEEPPATH: COMPANY OVERVIEW
  • TABLE 269 4D PATH INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 5 AI IN PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION
  • FIGURE 6 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN PATHOLOGY
  • FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029)
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 TOP-DOWN APPROACH
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 16 DEVELOPMENT OF CNNS AND AI LEARNING MODELS TO PROPEL MARKET
  • FIGURE 17 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 19 US TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)
  • FIGURE 22 AI IN PATHOLOGY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 23 ECOSYSTEM ANALYSIS
  • FIGURE 24 VALUE CHAIN ANALYSIS
  • FIGURE 25 EUROPE: IVDR TIMELINE
  • FIGURE 26 THERE IS MODERATE-TO-HIGH COMPETITIVE INTENSITY AMONG MARKET PLAYERS
  • FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2015−OCTOBER 2024
  • FIGURE 28 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN PATHOLOGY PATENTS (JANUARY 2015 TO MAY 2024)
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS
  • FIGURE 30 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS
  • FIGURE 31 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET
  • FIGURE 32 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY
  • FIGURE 33 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS FOR AI IN PATHOLOGY MARKET, 2019−2023
  • FIGURE 36 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2023)
  • FIGURE 37 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 38 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 39 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF LIFE SCIENCE ANALYTICS VENDORS
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 AI IN PATHOLOGY MARKET: BRAND/PRODUCT COMPARISON ANALYSIS
  • FIGURE 43 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 45 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2023)

This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

Secondary Research

This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, white papers, annual reports, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the AI in pathology market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the AI in pathology market. Primary sources from the demand side included personnel from pharmaceutical & biopharmaceutical companies, research institutes, and hospitals (small, medium-sized, and large hospitals).

A breakdown of the primary respondents is provided below:

*C-level primaries include CEOs, CFOs, COOs, and VPs.

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the AI in pathology market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

The size of the AI in pathology market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as given below:

  • Revenues for individual companies were gathered from public sources and databases.
  • Shares of leading players in the AI in pathology market were gathered from secondary sources to the extent available. In certain cases, shares of AI in pathology businesses have been ascertained after a detailed analysis of various parameters including product portfolios, market positioning, selling price, and geographic reach & strength. 
  • Individual shares or revenue estimates were validated through interviews with experts.
  • The total revenue in the AI in pathology market was determined by extrapolating the Market share data of major companies.

Market Definition

The AI in pathology market refers to the commercial space where companies develop, market, and provide products and services that incorporate artificial intelligence technologies specifically designed for pathology applications. This market focuses on leveraging AI algorithms, machine learning techniques, and advanced computational tools to enhance and automate various aspects of the pathology workflow.

This report provides a close look at AI in pathology market. It offers applications in drug discovery, disease diagnosis & prognosis, clinical workflow, and training & education.

Stakeholders

  • Pathologists
  • Suppliers And Distributors of Digital Pathology Equipment
  • AI System Providers
  • Medical Research and Biopharmaceutical Companies
  • Pharmaceutical Companies and Cros
  • Hospitals and Clinics
  • Laboratories
  • Regulatory Bodies
  • Medical Research Institutes
  • Artificial Intelligence (AI) in Pathology Solution Providers
  • Universities and Research Organizations
  • Forums, Alliances, and Associations
  • Academic Research Institutes
  • Technology Providers
  • Healthcare Payers

Report Objectives

  • To define, describe, and forecast the AI in pathology market by offering, neural networks, functions, use case, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies in the AI in pathology market
  • To benchmark players operating in the AI in pathology market using the Competitive Leadership Mapping framework, which analyzes key market players and start-ups on various parameters within the broad categories of market share/rank and product/service footprint
  • To track and analyze competitive developments such as product launches, expansions, agreements, partnerships, collaborations, product approvals, investments, and acquisitions to strengthen their market presence in the AI in pathology market.

 

Previous Versions of this Report

Al in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical workflow), End User (Hospital, Labs, Pharma/Biotech), & Region - Global Forecast to 2029

Report Code HIT 8721
Published in Jul, 2023, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.

By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in AI in Pathology Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2025 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status